{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:15:33Z","timestamp":1788171333668,"version":"build-2803163510"},"reference-count":152,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Targeted protein degradation (TPD) represents a whole new paradigm in cell-level therapeutic design, with its ability to remove target proteins, normally through the endogenous proteasomal, lysosomal, or autophagic systems, rather than the traditional occupancy-driven inhibition approach. But the clinical efficacy of degraders is becoming more restricted based on delivery rather than efficacy only. Many proteolysis-targeting chimeras and new proximity-inducing systems have low solubility, are impermeable, are pharmacodynamically complicated, lack tissue selectivity, and cannot fully access the intracellular space. Nanomedicine and PD platforms could provide strategies not only to overcome these challenges, but also to provide other advantages, including enhancing exposure to degraders, biodistribution, controlled release, and context-dependent activation. This critical review is an outline of all lipid, polymeric, inorganic, biomimetic, targeted, activatable, and self-assembling delivery systems for TPD. We assess compositional considerations, in vitro and in vivo evidence, challenges for translation, and clinical endpoints required to support delivery-enabled degradation. Trusted TPD therapeutics need to relate different aspects of their design, such as degrader chemistry, carrier structure, disease biology, and pharmacodynamic biomarkers, to one another. Further investigations are needed to establish intact delivery of the degrader to the target, target depletion in relevant tissues, prolonged pharmacodynamics, favorable safety, and compelling therapeutic benefit relative to free degraders or traditional inhibitors. Thus, it is important to view delivery not simply as an additional step during formulation but as a design principle necessary for the reliable clinical outcome of degradation medicine.<\/jats:p>","DOI":"10.3390\/pharmaceutics18091097","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:21:19Z","timestamp":1788168079000},"page":"1097","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Delivering Degradation: Nanomedicine and Programmable Proximity Platforms for Targeted Protein Degradation"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5562-6703","authenticated-orcid":false,"given":"Adnan","family":"Amin","sequence":"first","affiliation":[{"name":"Department of Life Sciences, Yeungnam University, Gyeongsan 38541, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Touseef","family":"Nawaz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Qurtuba University of Science and Information Technology, Peshawar 25100, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7881-8625","authenticated-orcid":false,"given":"Oberdan","family":"Oliveira Ferreira","sequence":"additional","affiliation":[{"name":"Program in Biotechnology, Federal University of Par\u00e1, Bel\u00e9m 66075-110, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mozaniel","family":"Santana de Oliveira","sequence":"additional","affiliation":[{"name":"Institute of Health Sciences, Federal University of Par\u00e1, Bel\u00e9m 66075-110, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.chembiol.2024.08.010","article-title":"New Therapies on the Horizon: Targeted Protein Degradation in Neuroscience","volume":"31","author":"Gregory","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1021\/acs.jcim.3c00603","article-title":"Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods","volume":"63","author":"Mostofian","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted Protein Degradation: Mechanisms, Strategies and Application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sincere, N.I., Anand, K., Ashique, S., Yang, J., and You, C. (2023). Protacs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies. Molecules, 28.","DOI":"10.3390\/molecules28104014"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wang, Y., Wei, T., Zhao, M., Huang, A., Sun, F., Chen, L., Lin, R., Xie, Y., Zhang, M., and Xu, S. (2024). Alkenyl Oxindole Is a Novel Protac Moiety That Recruits the Crl4dcaf11 E3 Ubiquitin Ligase Complex for Targeted Protein Degradation. PLoS Biol., 22.","DOI":"10.1371\/journal.pbio.3002550"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41594-025-01738-8","article-title":"Cereblon Induces G3bp2 Neosubstrate Degradation Using Molecular Surface Mimicry","volume":"33","author":"Annunziato","year":"2026","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"eadf6249","DOI":"10.1126\/science.adf6249","article-title":"Elucidating the Cellular Determinants of Targeted Membrane Protein Degradation by Lysosome-Targeting Chimeras","volume":"382","author":"Ahn","year":"2023","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1021\/acschembio.2c00185","article-title":"Roadmap for Optimizing and Broadening Antibody-Based Protacs for Degradation of Cell Surface Proteins","volume":"17","author":"Gramespacher","year":"2022","journal-title":"ACS Chem. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41419-026-08835-6","article-title":"Proteasome Inhibition Enhances Lysosome-Mediated Targeted Protein Degradation","volume":"17","author":"Elshazly","year":"2026","journal-title":"Cell Death Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1021\/acsmedchemlett.3c00161","article-title":"Discovery of Novel Pde\u03b4 Autophagic Degraders: A Case Study of Autophagy-Tethering Compound (Attec)","volume":"15","author":"Bao","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"16666","DOI":"10.1021\/acs.jmedchem.5c01497","article-title":"Linker Methylation as a Strategy to Enhance Protac Oral Bioavailability: Insights from Molecular Properties and Conformational Analysis","volume":"68","author":"Ermondi","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_12","first-page":"721","article-title":"Molecular Properties, Including Chameleonicity, as Essential Tools for Designing the Next Generation of Oral Beyond Rule of Five Drugs","volume":"12","author":"Caron","year":"2024","journal-title":"ADMET DMPK"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12967-025-07610-z","article-title":"Targeted Protein Degradation: Species, Diseases and Efficient Utilization","volume":"24","author":"Yue","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/1061186X.2023.2185247","article-title":"Albumin-Encapsulated Hsp90-Protac Bp3 Nanoparticles Not Only Retain Protein Degradation Ability but Also Enhance the Antitumour Activity of Bp3 in Vivo","volume":"31","author":"Jiang","year":"2023","journal-title":"J. Drug Target."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2020","DOI":"10.1002\/wnan.2020","article-title":"Nanotechnology-Enabled Targeted Protein Degradation for Cancer Therapeutics","volume":"16","author":"Zhao","year":"2024","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2207778","DOI":"10.1002\/smll.202207778","article-title":"Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer","volume":"19","author":"Lin","year":"2023","journal-title":"Small"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1038\/s41467-025-60039-2","article-title":"DNA Nanoflower Oligo-Protac for Targeted Degradation of Fus to Treat Neurodegenerative Diseases","volume":"16","author":"Ge","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e202510641","DOI":"10.1002\/ange.202510641","article-title":"Tandem-Activatable Protac Prodrug for Tumor Biomarker-Driven near-Infrared Opto-Proteolysis","volume":"137","author":"Lu","year":"2025","journal-title":"Angew. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17595","DOI":"10.1039\/D5SC04859A","article-title":"Rational Design of the Linkers in Targeting Chimeras","volume":"16","author":"Duan","year":"2025","journal-title":"Chem. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e202315997","DOI":"10.1002\/anie.202315997","article-title":"Photoswitchable Protacs for Reversible and Spatiotemporal Regulation of Nampt and Nad+","volume":"63","author":"Cheng","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00432-026-06482-0","article-title":"Knowledge Mapping and Bibliometric Insights of Scientific Research on Targeted Protein Degradation in Oncology","volume":"152","author":"Sweileh","year":"2026","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Su, G., Wang, Y., and Yao, L. (2026). Research Trends and Emerging Frontiers in Proteolysis Targeting Chimeras (Protacs): A Bibliometric Analysis of 2630 Publications (2001\u20132025). Pharmaceuticals, 19.","DOI":"10.3390\/ph19070988"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1021\/acs.jmedchem.4c02492","article-title":"Impact of Linker Composition on Vhl Protac Cell Permeability","volume":"68","author":"Abeje","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41392-024-01983-1","article-title":"Sequential Responsive Nano-Protacs for Precise Intracellular Delivery and Enhanced Degradation Efficacy in Colorectal Cancer Therapy","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13328","DOI":"10.1021\/jacs.4c18354","article-title":"Rational Design of Protac Linkers Featuring Ferrocene as a Molecular Hinge to Enable Dynamic Conformational Changes","volume":"147","author":"Salerno","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/17460441.2025.2467195","article-title":"Finding a Needle in the Haystack: Adme and Pharmacokinetics\/Pharmacodynamics Characterization and Optimization Towards Orally Available Bifunctional Protein Degraders","volume":"20","author":"Apprato","year":"2025","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e01384","DOI":"10.1002\/advs.202501384","article-title":"Remodeling the Physicochemical and Pharmacokinetic Properties of Protac Via Lipid Nanodisks for Cancer Therapy","volume":"12","author":"Pan","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1021\/acs.chemrev.5c00800","article-title":"Methods to Study the Molecular Mechanism and Drive the Design of Protein Degraders","volume":"126","author":"Crowe","year":"2026","journal-title":"Chem. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.7150\/thno.130510","article-title":"Esterase-Responsive Albumin-Binding Protac-Mediated Brd4 Degradation for Cancer Immunotherapy","volume":"16","author":"Lee","year":"2026","journal-title":"Theranostics"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Wu, X., Shu, Y., Zheng, Y.-R., Zhang, P., Cong, H., Zou, Y., Cai, H., and Zha, Z. (2025). Recent Advances in Nanomedicine: Cutting-Edge Research on Nano-Protac Delivery Systems for Cancer Therapy. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17081037"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1038\/s41467-024-50235-x","article-title":"Lipid-Mediated Intracellular Delivery of Recombinant Bioprotacs for the Rapid Degradation of Undruggable Proteins","volume":"15","author":"Chan","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1038\/s41467-026-71246-w","article-title":"Cartilage Targeting Hydrogel Nanoplatform Degrades Brd4 to Alleviate Osteoarthritis Via Nav1.7 Axis","volume":"17","author":"Zhao","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"102949","DOI":"10.1016\/j.mtbio.2026.102949","article-title":"Revolutionizing Protein Degradation: Harnessing Nanoparticles for Protac Delivery","volume":"37","author":"Fan","year":"2026","journal-title":"Mater. Today Bio"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2207439","DOI":"10.1002\/advs.202207439","article-title":"Glutathione-Scavenging Nanoparticle-Mediated Protacs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e202218128","DOI":"10.1002\/anie.202218128","article-title":"Targeted Degradation of Pd-L1 and Activation of the Sting Pathway by Carbon-Dot-Based Protacs for Cancer Immunotherapy","volume":"62","author":"Su","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2401051","DOI":"10.1002\/marc.202401051","article-title":"Integrating Proteolysis-Targeting Chimeras (Protacs) with Delivery Systems for More Efficient and Precise Targeted Protein Degradation","volume":"46","author":"Lin","year":"2025","journal-title":"Macromol. Rapid Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1038\/s41401-024-01266-z","article-title":"Tumor-Targeted Protac Prodrug Nanoplatform Enables Precise Protein Degradation and Combination Cancer Therapy","volume":"45","author":"Zou","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1021\/acsnano.5c20138","article-title":"Coassembled Prodrug Nanoparticles Mitigating the Acquired Resistance to Protein Degradation Therapy","volume":"20","author":"Gao","year":"2026","journal-title":"ACS Nano"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1016\/j.apsb.2025.06.028","article-title":"Activatable Protac Nanoassembly for Photodynamic Ptp1b Proteolysis Enhances Glioblastoma Immunotherapy","volume":"15","author":"Jang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e202308049","DOI":"10.1002\/anie.202308049","article-title":"Nano Proteolysis Targeting Chimeras (Protacs) with Anti-Hook Effect for Tumor Therapy","volume":"62","author":"Zhang","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-025-02444-z","article-title":"In Vivo Self-Assembled Nano-Protac for the Dual Degradation of Ar and Hsp90 to Overcome Castration-Resistant Prostate Cancer Resistance","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41392-025-02405-6","article-title":"Reprogramming of Cancer Metabolism Via Photoresponsive Nano-Protac Enhances Pyroptosis-Mediated Immunotherapy","volume":"10","author":"Park","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s44395-025-00021-5","article-title":"Techniques in the Characterization of Lipid-Based Nanotherapeutics: State of the Art, Challenges, and Future Direction","volume":"1","author":"Pattnaik","year":"2025","journal-title":"Discov. Pharm. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Viegas, C., Patr\u00edcio, A., Prata, J., Nadhman, A., Chintamaneni, P., and Fonte, P. (2023). Solid Lipid Nanoparticles Vs. Nanostructured Lipid Carriers: A Comparative Review. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15061593"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e202503958","DOI":"10.1002\/anie.202503958","article-title":"Nanoparticle-Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology","volume":"64","author":"Baker","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e20235","DOI":"10.1002\/anie.202520235","article-title":"Ionizable Nano-Protac Overcomes Endosomal Entrapment for Enhanced Lrg1 Degradation and Tumor Suppression","volume":"65","author":"Min","year":"2025","journal-title":"Angew. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.1021\/jacs.4c17827","article-title":"Chemoproteomics-Enabled De Novo Proteolysis Targeting Chimera Discovery Platform Identifies a Metallothionein Degrader to Probe Its Role in Cancer","volume":"147","author":"Racioppo","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e20774","DOI":"10.1002\/ange.202520774","article-title":"Split-Deliver-Click: Tumor-Specific Protein Degradation Via \u201cand\u201d Logic-Gated in-Cell Bioorthogonal Clicking of Protacs","volume":"138","author":"Dong","year":"2026","journal-title":"Angew. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"abq2216","DOI":"10.1126\/sciadv.abq2216","article-title":"Hypoxia Deactivates Epigenetic Feedbacks Via Enzyme-Derived Clicking Proteolysis-Targeting Chimeras","volume":"8","author":"Cong","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"14828","DOI":"10.1021\/acsnano.6c04279","article-title":"Logic-Gated Bioorthogonal in Situ Synthesis of Proteolysis-Targeting Chimeras for Precise Protein Degradation and Synergistic Immunotherapy","volume":"20","author":"Wu","year":"2026","journal-title":"ACS Nano"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e2528760123","DOI":"10.1073\/pnas.2528760123","article-title":"Light-Controlled Disruption of Cancer Cell Dormancy Via Photoswitchable Stress Hormone Receptor Degraders","volume":"123","author":"Freitag","year":"2026","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"168","DOI":"10.14336\/AD.2024.0206-1","article-title":"Nanomaterials in Medicine: Understanding Cellular Uptake, Localization, and Retention for Enhanced Disease Diagnosis and Therapy","volume":"16","author":"Peng","year":"2024","journal-title":"Aging Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"122753","DOI":"10.1016\/j.ijpharm.2023.122753","article-title":"Lipid-Based Nanoparticles: Enhanced Cellular Uptake Via Surface Thiolation","volume":"635","author":"Knoll","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1038\/s41467-025-60959-z","article-title":"Cellular and Biophysical Barriers to Lipid Nanoparticle Mediated Delivery of Rna to the Cytosol","volume":"16","author":"Johansson","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Syahputra, E.W., Lee, H., Cho, H., Park, H., Park, K.-S., and Hwang, D. (2025). Protac Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17040501"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s42004-026-01898-8","article-title":"A generalizable Assay for Intracellular Accumulation to Profile Cytosolic Drug Delivery in Mammalian Cells","volume":"9","author":"Bhandari","year":"2026","journal-title":"Commun. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-Based Analysis of Lipid Nanoparticle\u2013Mediated Sirna Delivery, Intracellular Trafficking and Endosomal Escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/nbt.3298","article-title":"Visualizing Lipid-Formulated Sirna Release from Endosomes and Target Gene Knockdown","volume":"33","author":"Wittrup","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s42003-021-01728-8","article-title":"A High-Throughput Galectin-9 Imaging Assay for Quantifying Nanoparticle Uptake, Endosomal Escape and Functional Rna Delivery","volume":"4","author":"Munson","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_60","first-page":"1136","article-title":"Gal8 Visualization of Endosome Disruption Predicts Carrier-Mediated Biologic Drug Intracellular Bioavailability","volume":"13","author":"Kilchrist","year":"2019","journal-title":"ACS Nano"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1038\/s41467-020-15300-1","article-title":"Imaging Small Molecule-Induced Endosomal Escape of Sirna","volume":"11","author":"Hedlund","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1038\/s41467-021-23997-x","article-title":"Unravelling Cytosolic Delivery of Cell Penetrating Peptides with a Quantitative Endosomal Escape Assay","volume":"12","author":"Teo","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11095-019-2725-1","article-title":"A Flow Cytometric Method to Quantify the Endosomal Escape of a Protein Toxin to the Cytosol of Target Cells","volume":"37","author":"Wensley","year":"2019","journal-title":"Pharm. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jchromb.2012.10.033","article-title":"Ultra-Sensitive Assay for Paclitaxel in Intracellular Compartments of A549 Cells Using Liquid Chromatography\u2013Tandem Mass Spectrometry","volume":"912","author":"Wang","year":"2013","journal-title":"J. Chromatogr. B"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13059-021-02267-5","article-title":"Single-Cell Proteomic and Transcriptomic Analysis of Macrophage Heterogeneity Using Scope2","volume":"22","author":"Specht","year":"2021","journal-title":"Genome Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41565-022-01146-9","article-title":"Nanoparticle Single-Cell Multiomic Readouts Reveal That Cell Heterogeneity Influences Lipid Nanoparticle-Mediated Messenger Rna Delivery","volume":"17","author":"Dobrowolski","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.sbi.2020.10.009","article-title":"Building Ubiquitination Machineries: E3 Ligase Multi-Subunit Assembly and Substrate Targeting by Protacs and Molecular Glues","volume":"67","author":"Ramachandran","year":"2020","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e202300530","DOI":"10.1002\/cmdc.202300530","article-title":"Kinetic Modeling of Protac-Induced Protein Degradation","volume":"18","author":"Zhao","year":"2023","journal-title":"ChemMedChem"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"17691","DOI":"10.1039\/D4SC03555K","article-title":"Dual-Ligand Protacs Mediate Superior Target Protein Degradation in Vitro and Therapeutic Efficacy in Vivo","volume":"15","author":"Chen","year":"2024","journal-title":"Chem. Sci."},{"key":"ref_70","first-page":"gkaf996","article-title":"Tpddb: The Comprehensive Database of Targeted Protein Degrader","volume":"54","author":"Qin","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.tips.2023.08.007","article-title":"Proteomic Approaches Advancing Targeted Protein Degradation","volume":"44","author":"Sathe","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e15159","DOI":"10.1002\/advs.202515159","article-title":"Discovery of Skp2-Recruiting Protacs for Target Protein Degradation","volume":"13","author":"Dong","year":"2026","journal-title":"Adv. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"21560","DOI":"10.1021\/jacs.5c02741","article-title":"An in-Cell Approach to Evaluate E3 Ligases for Use in Targeted Protein Degradation","volume":"147","author":"Zheng","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1021\/acschembio.4c00812","article-title":"Workflow for E3 Ligase Ligand Validation for Protac Development","volume":"20","author":"Weckesser","year":"2025","journal-title":"ACS Chem. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1021\/acs.biochem.1c00464","article-title":"Ligandability of E3 Ligases for Targeted Protein Degradation Applications","volume":"62","author":"Belcher","year":"2021","journal-title":"Biochemistry"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.1038\/s41467-024-50735-w","article-title":"A Region-Confined Protac Nanoplatform for Spatiotemporally Tunable Protein Degradation and Enhanced Cancer Therapy","volume":"15","author":"Gao","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1021\/jacsau.5c00422","article-title":"DNA-Programmable Protein Degradation: Dynamic Control of Proteolysis-Targeting Chimera Activity Via DNA Hybridization and Strand Displacement","volume":"5","author":"Kashyap","year":"2025","journal-title":"Jacs Au"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e202415323","DOI":"10.1002\/anie.202415323","article-title":"Microrna-Triggered Programmable DNA-Encoded Pre-Protacs for Cell-Selective and Controlled Protein Degradation","volume":"64","author":"Zhan","year":"2024","journal-title":"Angew. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1038\/s41467-025-62829-0","article-title":"Unbiased Mapping of Cereblon Neosubstrate Landscape by High-Throughput Proteomics","volume":"16","author":"Steger","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41565-023-01514-z","article-title":"Inhibition of Acute Complement Responses Towards Bolus-Injected Nanoparticles Using Targeted Short-Circulating Regulatory Proteins","volume":"19","author":"Li","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/s41551-024-01256-w","article-title":"Amine Headgroups in Ionizable Lipids Drive Immune Responses to Lipid Nanoparticles by Binding to the Receptors Tlr4 and Cd1d","volume":"8","author":"Chaudhary","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"14605","DOI":"10.1021\/acsnano.5c00484","article-title":"Design Considerations for Organ-Selective Nanoparticles","volume":"19","author":"Baek","year":"2025","journal-title":"ACS Nano"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e2507922122","DOI":"10.1073\/pnas.2507922122","article-title":"Influence of the Protein Corona on Hematopoietic Stem and Progenitor Cell Uptake and Macrophage Clearance of Membrane-Wrapped Nanoparticles","volume":"122","author":"Sterin","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"eadu2292","DOI":"10.1126\/sciadv.adu2292","article-title":"Tumor Microenvironment\u2013Targeted Protac Nanoparticle Self-Assembly Broadly Predicted by Structural Descriptors","volume":"11","author":"Vogt","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1021\/acs.molpharmaceut.4c00663","article-title":"Folate Receptor B (Fr\u03b2) Expression on Myeloid Cells and the Impact of Reticuloendothelial System on Folate-Functionalized Nanoparticles\u2019 Biodistribution in Cancer","volume":"21","author":"Goksen","year":"2024","journal-title":"Mol. Pharm."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"217454","DOI":"10.1016\/j.canlet.2025.217454","article-title":"Interrogation of the Tumor Microenvironment by Nanoparticles","volume":"612","author":"Panja","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"113722","DOI":"10.1016\/j.jconrel.2025.113722","article-title":"Sonopermeation Combined with Stroma Normalization Enables Complete Cure Using Nano-Immunotherapy in Murine Breast Tumors","volume":"382","author":"Neophytou","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12951-025-03985-9","article-title":"Nano-Protacs for Precision Medicine: Engineering Strategies for Enhanced Targeting and Potency","volume":"24","author":"Yang","year":"2026","journal-title":"J. Nanobiotechnol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"9371","DOI":"10.1021\/acsnano.5c21154","article-title":"Carrier-Free Nano-Proteolysis Targeting Chimeras Enable Selective Protein Degradation and Enhance Photoimmunometabolic Therapy against Lung Adenocarcinoma","volume":"20","author":"Wang","year":"2026","journal-title":"ACS Nano"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41589-025-01846-y","article-title":"Pharmacodynamics of Akt Drugs Revealed by a Kinase-Modulated Bioluminescent Indicator","volume":"21","author":"Wu","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Haid, R., and Reichel, A. (2023). A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (Protacs). Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15010195"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"102767","DOI":"10.1016\/j.mtbio.2026.102767","article-title":"Ginsenoside Rh2- Functionalized Liposomes Enhanced Brd4-Protac Delivery and Antitumor Efficacy Via Improved Tumor Targeting and Ecm Remodeling","volume":"36","author":"Wen","year":"2026","journal-title":"Mater. Today Bio"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/17435390.2024.2361687","article-title":"Evaluation of the Biodistribution and Preliminary Safety Profile of a Novel Brain-Targeted Manganese Dioxide-Based Nanotheranostic System for Alzheimer\u2019s Disease","volume":"18","author":"Li","year":"2024","journal-title":"Nanotoxicology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e202306824","DOI":"10.1002\/ange.202306824","article-title":"Stimuli-Responsive Protacs for Controlled Protein Degradation","volume":"135","author":"An","year":"2023","journal-title":"Angew. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e202421713","DOI":"10.1002\/ange.202421713","article-title":"In Vivo Self-Assembly of Protacs by Bioorthogonal Chemistry for Precision Cancer Therapy","volume":"137","author":"Xie","year":"2024","journal-title":"Angew. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e20250016","DOI":"10.1002\/INMD.20250016","article-title":"Patient-Derived Xenograft Models in Pan-Cancer: From Bench to Clinic","volume":"3","author":"Li","year":"2025","journal-title":"Interdiscip. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12951-026-04056-3","article-title":"Recent Advances in Nanomaterial-Based Precision Medicine for Orthotopic Tumor Therapy","volume":"24","author":"Luo","year":"2026","journal-title":"J. Nanobiotechnol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e70068","DOI":"10.1002\/cai2.70068","article-title":"Clinical Breakthrough in Targeted Protein Degradation: Reflections on the Approval of Arv-471","volume":"5","author":"Rao","year":"2026","journal-title":"Cancer Innov."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Wu, N., Xu, Z., Dai, S., and Wang, Q. (2026). Research Progress and Future Perspectives in Proteolysis-Targeting Chimeras. Front. Pharmacol., 17.","DOI":"10.3389\/fphar.2026.1815569"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14728222.2025.2482557","article-title":"Can We Develop Effective Direct or Indirect Inhibitors of Transcription Factors? On the Clinical Evolution of Protein Degraders for Multiple Myeloma Therapy","volume":"29","author":"Meli","year":"2025","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cpt.2985","article-title":"Clinical Translation of Targeted Protein Degraders","volume":"114","author":"Kong","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Smoragiewicz, M., Bernard-Tessier, A., Linch, M., Shen, J., Shore, N., Parikh, O., Chi, K., Sokolova, A., Culine, S., and McKean, M. (2026). Phase 1b Trial of Bavdegalutamide (Arv-110) in Combination with Abiraterone for Metastatic Prostate Cancer. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-26-0253"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"Protac Targeted Protein Degraders: The Past Is Prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1124\/dmd.122.001154","article-title":"Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders","volume":"51","author":"Volak","year":"2023","journal-title":"Drug Metab. Dispos."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s13346-022-01262-y","article-title":"Nanomedicines and Nanocarriers in Clinical Trials: Surfing through Regulatory Requirements and Physico-Chemical Critical Quality Attributes","volume":"13","author":"Dri","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_106","first-page":"gkaf811","article-title":"Molgluedb: An Online Database of Molecular Glues","volume":"54","author":"Wang","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/10409238.2025.2564068","article-title":"From Serendipity to Strategy: Molecular Glue Degraders in Cancer Therapeutics","volume":"60","author":"Darling","year":"2025","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.1021\/acs.jmedchem.3c00740","article-title":"Physicochemical Property Determinants of Oral Absorption for Protac Protein Degraders","volume":"66","author":"Hornberger","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/01926233241300452","article-title":"Session 5: Protein Degraders","volume":"52","author":"Palyada","year":"2024","journal-title":"Toxicol. Pathol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted Protein Degradation: Advances in Drug Discovery and Clinical Practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-Targeting Chimera (Protac) Delivery System: Advancing Protein Degraders Towards Clinical Translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_112","first-page":"500","article-title":"Current Hurdles to the Translation of Nanomedicines from Bench to the Clinic","volume":"12","author":"Carreira","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","article-title":"Lipid-Based Nanoparticles for Drug\/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development","volume":"3","author":"Mehta","year":"2023","journal-title":"ACS Mater. Au"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"115861","DOI":"10.1016\/j.addr.2026.115861","article-title":"Self-Assembled Nano-Protacs: Bridging Chemical Design and Biological Barriers in Targeted Protein Degradation","volume":"234","author":"Zhang","year":"2026","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Khairnar, S., Pagare, P., Thakre, A., Nambiar, A., Junnuthula, V., Abraham, M., Kolimi, P., Nyavanandi, D., and Dyawanapelly, S. (2022). Review on the Scale-up Methods for the Preparation of Solid Lipid Nanoparticles. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091886"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.xphs.2022.11.001","article-title":"The Storage and in-Use Stability of Mrna Vaccines and Therapeutics: Not a Cold Case","volume":"112","author":"Blenke","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1111\/bph.17332","article-title":"Translational Modelling to Predict Human Pharmacokinetics and Pharmacodynamics of a Bruton\u2019s Tyrosine Kinase-Targeted Protein Degrader Bgb-16673","volume":"181","author":"Wu","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Wu, M.-H., Zhao, Y., Zhang, C., and Pu, K. (2024). Advancing Proteolysis Targeting Chimera (Protac) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment. ACS Nano.","DOI":"10.1021\/acsnano.4c09800"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/17576180.2026.2624362","article-title":"Progress and Promise of Pharmacodynamic Biomarkers: Novel Strategies and Assay Considerations in Drug Development","volume":"18","author":"Quadrini","year":"2026","journal-title":"Bioanalysis"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Peralta-Cuevas, E., Degollado-Hern\u00e1ndez, N., Mart\u00ednez-Ort\u00edz, I., Gutierrez-Onofre, A., Garcia-Atutxa, I., and Villanueva-Flores, F. (2026). How Do Nanoparticle Properties Shape Pharmacokinetics and Pharmacodynamics? A Mechanistic Review. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1704814"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/02652048.2025.2495290","article-title":"Recent Developments in Sustained-Release and Targeted Drug Delivery Applications of Solid Lipid Nanoparticles","volume":"42","author":"Hussein","year":"2025","journal-title":"J. Microencapsul."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e70045","DOI":"10.1002\/bmm2.70045","article-title":"Advancing Design Strategies in Smart Stimulus-Responsive Liposomes for Drug Release and Nanomedicine","volume":"4","author":"Guo","year":"2026","journal-title":"BMEMat"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Mathis, B., Zaboronok, A., Shi, Y., Nagumo, Y., Nishiyama, H., and Hiramatsu, Y. (2026). Nanoparticle Clearance and New Horizons in Engineered Drug Delivery. Pharmaceutics, 18.","DOI":"10.3390\/pharmaceutics18040471"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Zawidlak-W\u0119grzy\u0144ska, B., and Rydz, J. (2026). Polymer Nanoparticles in Medical Applications\u2014Future Directions. Nanomaterials, 16.","DOI":"10.3390\/nano16100630"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"105837","DOI":"10.1016\/j.ebiom.2025.105837","article-title":"Inflammation-Modulating Polymeric Nanoparticles: Design Strategies, Mechanisms, and Therapeutic Applications","volume":"118","author":"Zhang","year":"2025","journal-title":"eBioMedicine"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"7742","DOI":"10.1021\/acsnano.4c12747","article-title":"Targeted Protein Degradation in Cancer Therapy Via Hydrophobic Polymer-Tagged Nanoparticles","volume":"19","author":"Lee","year":"2025","journal-title":"ACS Nano"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.7150\/thno.128435","article-title":"Recent Advances of Metal-Organic Frameworks (Mofs) for Drug Delivery, Cancer Imaging and Theranostics","volume":"16","author":"Yu","year":"2026","journal-title":"Theranostics"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Parang, K., Vadlapatla, R., Koomer, A., Moran, V., Jackson, L., and Shirazi, A. (2026). Iron-Based Nanoparticles as Delivery Tools. Pharmaceuticals, 19.","DOI":"10.3390\/ph19050654"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/s12951-026-04372-8","article-title":"The Application of Drug Delivery Systems Based on Targeted Protein Degradation Chimeras in Disease Treatment Strategies","volume":"24","author":"Lin","year":"2026","journal-title":"J. Nanobiotechnol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Feng, J., He, D., Chen, J., Li, M., Luo, J., Han, Y., Wei, X., Ren, S., Wang, Z., and Wu, Y. (2025). Cell Membrane Biomimetic Nanoplatforms: A New Strategy for Immune Escape and Precision Targeted Therapy. Mater. Today Bio, 35.","DOI":"10.1016\/j.mtbio.2025.102343"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"021505","DOI":"10.1063\/5.0315665","article-title":"Platelet Membrane-Coated Nanoparticles: Bioengineering Principles, Quality Control, and Translational Opportunities","volume":"10","author":"Mdlovu","year":"2026","journal-title":"APL Bioeng."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ymthe.2025.02.047","article-title":"Using Aptamers for Targeted Delivery of Rna Therapies","volume":"33","author":"Driscoll","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e202400326","DOI":"10.1002\/cmdc.202400326","article-title":"Conditional Protac: Recent Strategies for Modulating Targeted Protein Degradation","volume":"19","author":"Yim","year":"2024","journal-title":"Chemmedchem"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e20975","DOI":"10.1002\/advs.202520975","article-title":"Bioorthogonal Sonodynamic Plug-and-Play Targeting Chimeras (Sdptac) for Precise Targeted Protein Degradation","volume":"13","author":"Bao","year":"2026","journal-title":"Adv. Sci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e20863","DOI":"10.1002\/advs.202520863","article-title":"Targeted Degradation of Eef2k by a Structure-Guided Protac Strategy for the Treatment of Triple-Negative Breast Cancer","volume":"13","author":"Cao","year":"2026","journal-title":"Adv. Sci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"107080","DOI":"10.4252\/wjsc.v17.i7.107080","article-title":"Engineering the Future of NANOMEDICINE: Strategic Approaches to Extracellular Vesicle-Based Drug Administration Regimens","volume":"17","author":"Ye","year":"2025","journal-title":"World J. Stem Cells"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"8433","DOI":"10.1039\/D3SC02361C","article-title":"Opportunities and Challenges of Protein-Based Targeted Protein Degradation","volume":"14","author":"Shen","year":"2023","journal-title":"Chem. Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1038\/s41467-022-32050-4","article-title":"Engineered Bioorthogonal Poly-Protac Nanoparticles for Tumour-Specific Protein Degradation and Precise Cancer Therapy","volume":"13","author":"Gao","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"110795","DOI":"10.1016\/j.colsurfb.2020.110795","article-title":"Targeted Degradation of Anaplastic Lymphoma Kinase by Gold Nanoparticle-Based Multi-Headed Proteolysis Targeting Chimeras","volume":"188","author":"Wang","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1021\/acs.nanolett.3c03148","article-title":"Targeted Protein Degradation Mediated by Genetically Engineered Lysosome-Targeting Exosomes","volume":"23","author":"Wang","year":"2023","journal-title":"Nano Lett."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"16642","DOI":"10.1021\/jacs.3c04109","article-title":"Self-Assembled Nano-Protac Enables near-Infrared Photodynamic Proteolysis for Cancer Therapy","volume":"145","author":"Wang","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"23299","DOI":"10.1002\/anie.202107347","article-title":"Aptamer-Protac Conjugates (Apcs) for Tumor-Specific Targeting in Breast Cancer","volume":"60","author":"He","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"TPS1114","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1114","article-title":"A Phase 1, First-in-Human, Open Label, Escalation and Expansion Study of Orm-5029, a Highly Potent Gspt1 Degrader Targeting Her2, in Patients with Her2-Expressing Advanced Solid Tumors","volume":"41","author":"Hurvitz","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_144","first-page":"1027","article-title":"Targeted Delivery of a Protac Induced Pde\u03b4 Degrader by a Biomimetic Drug Delivery System for Enhanced Cytotoxicity against Pancreatic Cancer Cells","volume":"12","author":"Fan","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1039\/D3CS00344B","article-title":"Targeted Protein Degradation Directly Engaging Lysosomes or Proteasomes","volume":"53","author":"Kim","year":"2024","journal-title":"Chem. Soc. Rev."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e20441","DOI":"10.1002\/advs.202520441","article-title":"Coacervate-Mediated Lysosome-Targeting Antibody Delivery for Protein Degradation","volume":"13","author":"Yuan","year":"2026","journal-title":"Adv. Sci."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"108077","DOI":"10.1016\/j.jbc.2024.108077","article-title":"Redirecting E3 Ubiquitin Ligases for Targeted Protein Degradation with Heterologous Recognition Domains","volume":"301","author":"Yang","year":"2024","journal-title":"J. Biol. Chem."},{"key":"ref_148","first-page":"255","article-title":"Self-Assembled Protacs Enable Protein Degradation to Reprogram the Tumor Microenvironment for Synergistically Enhanced Colorectal Cancer Immunotherapy","volume":"43","author":"Lu","year":"2024","journal-title":"Bioact. Mater."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e70192","DOI":"10.1002\/ddr.70192","article-title":"Next-Generation Proteolysis-Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation","volume":"86","author":"Nafie","year":"2025","journal-title":"Drug Dev. Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1021\/jacsau.6c00033","article-title":"Data-Driven Design of Protac Linkers to Improve Protac Cell Membrane Permeability","volume":"6","author":"Murakami","year":"2026","journal-title":"Jacs Au"},{"key":"ref_151","first-page":"100393","article-title":"Making in Vitro Release and Formulation Data Ai-Ready: A Foundation for Streamlined Nanomedicine Development","volume":"10","author":"Yanes","year":"2025","journal-title":"Int. J. Pharm. X"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12951-026-04266-9","article-title":"Dual Tumor Microenvironment-Responsive Albumin Nanoplatform Integrates Conditional Protac Activation with Starvation and Ferroptosis for Synergistic Cancer Therapy","volume":"24","author":"Lin","year":"2026","journal-title":"J. Nanobiotechnol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1097\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:25:37Z","timestamp":1788168337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":152,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pharmaceutics18091097"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18091097","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}